Poging GOUD - Vrij
Middle East Leverages AI for Real Gains
BioSpectrum Asia
|BioSpectrum Asia Oct 2025
The Middle East is not only investing in digital healthcare, but building around it. From national health strategies to growing startup hubs, the region is turning infrastructure gaps into launch pads. With a projected compound annual growth rate (CAGR) of 9.2 per cent, the Middle East's digital healthcare market is poised to reach $7.9 billion by 2028. Moreover, the United Arab Emirates (UAE) has now launched a strategic initiative aimed at strengthening its position as a leading global hub for entrepreneurship and innovation, especially with the advent of artificial intelligence (AI) and other technologies. But there are certain barriers affecting technology adoption and startup scale-up in the region. Let's look into this in detail.
The Middle East is not only investing in digital healthcare, but building around it. From national health strategies to growing startup hubs, the region is turning infrastructure gaps into launch pads. With a projected compound annual growth rate (CAGR) of 9.2 per cent, the Middle East's digital healthcare market is poised to reach $7.9 billion by 2028. Moreover, the United Arab Emirates (UAE) has now launched a strategic initiative aimed at strengthening its position as a leading global hub for entrepreneurship and innovation, especially with the advent of artificial intelligence (AI) and other technologies. But there are certain barriers affecting technology adoption and startup scale-up in the region.
From virtual hospitals to AI-powered diagnostics, the Middle East is rapidly becoming one of the world's most dynamic frontiers for digital health. Governments across the region are making bold investments in healthcare innovation. For instance, Saudi Arabia's healthcare ambitions under Vision 2030 have positioned the Kingdom as a global leader in digital health. The kingdom established the Saudi Data & AI Authority (SDAIA) to steer AI policy and launched a national strategy to develop AI and data capabilities. Saudi Arabia has set targets like creating 300 AI-driven startups and attracting $20 billion in AI investments by 2030. Also, Saudi's HUMAIN (a Public Investment Fund-backed AI company) plans a $10 billion venture fund to fuel AI startups.
Dit verhaal komt uit de BioSpectrum Asia Oct 2025-editie van BioSpectrum Asia.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN BioSpectrum Asia
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Listen
Translate
Change font size

